2023-04-27 18:15:47
Pharmaceutical Eli Lilly reported, this Thursday (27/4), that its experimental drug once morest type 2 diabetes helped patients with obesity or overweight to lose up to 15.7% of body weight. The results were found in a large study that is at an advanced stage.
Volunteers who received a high dose of the drug Mounjaro – also known as tirzepatide – lost an average of 15 kilos at the end of 72 weeks. The research included 938 adults with obesity or overweight and type 2 diabetes.
More on the subject
-
Well-being
Rivotril and Ozempic generation: is simultaneous use of drugs allowed?
-
Health
On TikTok, users report hair loss following using Ozempic
-
Health
Study: Soup and shake diet can reverse diabetes diagnosis
-
Health
Discover 5 vaccines recommended especially for people with diabetes
About 82% of people using the 10 mg dose and 86.4% of those using the 15 mg dose lost at least 5% of their body weight, compared with 30.5% of those in the placebo group who also lost weight. .
Among participants on the 10 mg dose, there was an average weight loss of 13.4% (13.5 kg). In those on the 15 mg dose group, the reduction achieved was 15.7% (15.6 kg), compared to those on placebo, where the average reduction was 3.3%, or 3.2 kg.
The new drug brought more efficient results than those of Ozempic, a diabetes drug that has been used “off label” for weight loss. A survey published in the New England Journal of Medicine in 2021 showed that semaglutide – Ozempic’s substance – provided a loss of up to 14.9% of weight.
The most frequently reported adverse events were nausea, diarrhea, vomiting and constipation. They occurred more frequently during the dose change period and were generally mild to moderate in severity.
Risk factors
Overweight and obesity are considered the main risk factors that lead to type 2 diabetes. This is because body fat causes insulin resistance. Weight control is indicated to complement the treatment of diabetes.
window._taboola = window._taboola || [];
_taboola.push({
mode: “thumbnails-c-3×1”,
container: “taboola-mid-article”,
placement: “Mid Article”,
target_type: “mix”
});
Tirzepatida was approved in May 2022 by the US Food and Drug Administration (FDA), equivalent to Anvisa in Brazil, under the name of Mounjaro for the treatment of type 2 diabetes. It is a glucose-dependent insulinotropic polypeptide receptor (GIP ) and glucagon-like peptide-1 (GLP-1) receptor agonist.
Eli Lilly said in a statement that it plans to ask the FDA for Mounjaro approval for the treatment of obese or overweight adults. “We expect regulatory action as early as the end of 2023,” the company said.
Get news from metropolises on your Telegram and stay on top of everything! Just access the channel:
The post Competitor of Ozempic: new medicine for diabetes reduces weight by 16% first appeared on Metropolis.
1682620953
#Competitor #Ozempic #drug #diabetes #reduces #weight
